These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 24016496)

  • 21. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons from platelet inhibition and patient outcomes.
    Held C
    Curr Opin Cardiol; 2012 Jul; 27(4):355-60. PubMed ID: 22565140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
    Husted S; James SK; Bach RG; Becker RC; Budaj A; Heras M; Himmelmann A; Horrow J; Katus HA; Lassila R; Morais J; Nicolau JC; Steg PG; Storey RF; Wojdyla D; Wallentin L;
    Eur Heart J; 2014 Jun; 35(23):1541-50. PubMed ID: 24682844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
    Levin LÅ; Wallentin L; Bernfort L; Andersson D; Storey RF; Bergström G; Lamm CJ; Janzon M; Kaul P
    Value Health; 2013 Jun; 16(4):574-80. PubMed ID: 23796291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
    Cheng JW
    Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
    Husted S
    Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
    Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Lim ST; Cannon CP; Katus HA; Wallentin L
    Am J Cardiol; 2011 Dec; 108(11):1542-6. PubMed ID: 21890085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
    Hansson EC; Rexius H; Dellborg M; Albertsson P; Jeppsson A
    Eur J Cardiothorac Surg; 2014 Oct; 46(4):699-705; discussion 705. PubMed ID: 24482383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
    Husted S; Harrington RA; Cannon CP; Storey RF; Mitchell P; Emanuelsson H
    Int J Clin Pract; 2009 Apr; 63(4):667-70. PubMed ID: 19335707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Steg PG; Harrington RA; Emanuelsson H; Katus HA; Mahaffey KW; Meier B; Storey RF; Wojdyla DM; Lewis BS; Maurer G; Wallentin L; James SK;
    Circulation; 2013 Sep; 128(10):1055-65. PubMed ID: 23900047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
    Armstrong PW; Westerhout CM; Fu Y; Harrington RA; Storey RF; Katus H; James S; Wallentin L
    Am J Med; 2013 Aug; 126(8):723-729.e1. PubMed ID: 23795897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
    J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
    Lindholm D; Varenhorst C; Cannon CP; Harrington RA; Himmelmann A; Maya J; Husted S; Steg PG; Cornel JH; Storey RF; Stevens SR; Wallentin L; James SK
    Eur Heart J; 2014 Aug; 35(31):2083-93. PubMed ID: 24727884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
    Varenhorst C; Alström U; Braun OÖ; Storey RF; Mahaffey KW; Bertilsson M; Cannon CP; Scirica BM; Himmelmann A; James SK; Wallentin L; Held C
    Heart; 2014 Nov; 100(22):1762-9. PubMed ID: 24957530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
    Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Cooper A; Cairns R; Cannon CP; Wallentin L
    Eur Heart J; 2011 Dec; 32(23):2945-53. PubMed ID: 21804104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R; Pocock SJ; Nikolsky E; Clayton T; Dangas GD; Kirtane AJ; Parise H; Fahy M; Manoukian SV; Feit F; Ohman ME; Witzenbichler B; Guagliumi G; Lansky AJ; Stone GW
    J Am Coll Cardiol; 2010 Jun; 55(23):2556-66. PubMed ID: 20513595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.